Insight Molecular Diagnostics Inc. is preparing for the FDA submission of its GraftAssureDx test kit by year-end, with a projected mid-2026 product launch. The company is focused on expanding its molecular diagnostic technology into the transplant market, aiming for significant revenue growth and free cash flow generation post-authorization. Momentum is building with clinical trial progress and strategic partnerships.
On track to submit GraftAssureDx for FDA review by year-end 2025.
positiveOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025.
positiveCMS improved reimbursement price for assay to $2,753 per result in May 2025.
positiveWelcomed new VP of Marketing, Steven Tahmooressi, with extensive experience in transplantation and oncology.
positiveReported Q3 2025 revenues of $260,000, a significant increase from $115,000 in Q3 2024.
positiveReported Q3 2025 gross profit of $139,000, representing a 53.5% gross margin.
positiveNet loss for Q3 2025 was $10.9 million, or ($0.34) per share.
negativeNet loss for the nine months ended September 30, 2025, was $27.3 million, or ($0.91) per share.
negativeTotal operating expenses in Q3 2025 were $11.2 million, with a significant portion attributed to non-cash items like change in fair value of contingent consideration ($3.4 million).
attentionResearch and development expenses increased 18% sequentially to $3.9 million in Q3 2025, reflecting increased investment in kitted product development.
attentionNet cash used in operating activities for Q3 2025 was $4.6 million, and $16.6 million for the nine months ended September 30, 2025.
negativeTotal liabilities of $53.1 billion exceed total assets of $43.9 billion, resulting in a shareholders' deficit of $9.2 billion.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Preparing to submit GraftAssureDx for FDA review by year-end 2025, with a projected mid-2026 product launch.
Focus on expanding into transplant testing for other organs, such as heart and lung.
Leveraging a decentralized testing approach using digital PCR technology.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.